News Article | February 21, 2017
Virtual reality medical imaging company takes distribution overseas to expand in research and clinical applications across medical fields MOUNTAIN VIEW, CA--(Marketwired - Feb 21, 2017) - EchoPixel today announced it has received CE Mark approval for the sale of its True 3D interactive virtual reality imaging technology. The certification marks a key development in the company's expansion as it continues to provide healthcare professionals with an intuitive, interactive tool for interpreting patient-specific anatomy and planning for complex surgeries. "There are incredible medical innovations taking place in the European market," noted Ron Schilling, PhD., CEO of EchoPixel, Inc. "This verification is a tremendous step for EchoPixel's growth as we expand our network of hospitals, research institutes, and clinics leveraging the system for diagnostics and surgical planning. This is the next step in bringing the 3D imaging revolution to healthcare systems around the world." The True 3D Viewer creates lifelike, dynamic scenes out of DICOM images including MRIs and CT scans. Using the technology, doctors can view, dissect, and interact with the scenes as if they were real physical objects. The system is currently in use at luminary sites across the United States. Dr. Judy Yee, MD, Vice Chair of Radiology and Biomedical Imaging at UCSF has been performing a clinical evaluation of the device's use for CT Colonography, describing the technology as a "game-changer" in clinical detection of flat lesions that can cause colon cancer. Physicians at Stanford University have been using True 3D to plan and perform complex pediatric heart surgeries, including a recent groundbreaking operation to successfully separate conjoined twins. Interventional cardiologists at Deborah Heart and Lung are mapping patient hearts to help physicians insert stents, and at the Lahey Clinic in Boston, interventional neuroradiologists are using the True 3D's precise measurements to size pipeline devices when treating brain aneurysms. In July, 2016, EchoPixel began a partnership with HP to supply the HP Zvr and workstation for clinical use with the True 3D Viewer software. The HP workstation provides a powerful tool for diagnostic imaging and surgical planning across the United States. About EchoPixel EchoPixel is building a new world of patient care with its groundbreaking medical visualization software. The company's FDA-cleared True 3D Viewer uses existing medical image datasets to create virtual reality environments of patient-specific anatomy, allowing physicians to view and dissect images just as they would real, physical objects. The technology aims to make reading medical images more intuitive, help physicians reach diagnosis, and assist in surgical planning. Leading institutions, including Stanford University, the University of California, San Francisco, the Cleveland Clinic, the Lahey Clinic, and more are using True 3D in clinical and research applications. EchoPixel is a privately held, venture backed company located in Mountain View, CA.
News Article | February 21, 2017
Suite of software tools built on EchoPixel's breakthrough Interactive Virtual Reality technology aim to provide fast, accurate, 3D models for a wide range of medical procedures MOUNTAIN VIEW, CA--(Marketwired - Feb 21, 2017) - EchoPixel today announced True 3D print support, a breakthrough set of software tools designed to assist physicians using models they create using their 3D printers Built on EchoPixel's True 3D Viewer software, the workflows allow medical professionals to visualize and interact with patient specific anatomy that can be directly converted into 3D printed models. This allows professionals to create their models with greater quality and accuracy, and to "print right, the first time". EchoPixel's existing True 3D Viewer software enables physicians to see and interact with medical images the way they would with real, physical objects. The system converts existing DICOM datasets into life-size virtual reality objects, allowing physicians to move, turn, dissect, and cut open virtual patient anatomy. The new software tools facilitate seamless transition to printing of 3D models, once a professional has determined the desired anatomy and orientation to print. "We believe there's a revolution happening in 3D medical modeling, and it's just getting started," said Ron Schilling, CEO of EchoPixel. "3D printing is a game changing technology, but it's not yet accepted as a widely effective clinical tool, primarily due to the cost and time restrictions. EchoPixel's Interactive Virtual Reality is a complementary technology that can enable truly effective 3D modeling for the first time. It has the potential to dramatically reduce time and cost investments." When supported by EchoPixel's software tools, 3D modeling has numerous potential benefits across a range of medical applications. These may include: "We're excited to establish 3D virtual viewing as part of our 3D program," said Steve Muyskens, M.D., cardiologist at Cook Children's Medical Center in Fort Worth, Texas. "Having this technology, in addition to 3D printing capabilities, allows Cook Children's cardiologists and cardiothoracic surgeons to improve the planning of complex procedures and surgeries. We believe this approach will eventually lead to less time in the operating room and fewer complications." EchoPixel will be demonstrating its True 3D Viewer and its Print Support functionality in HP's booth #1979 at HIMSS 2017. About EchoPixel EchoPixel is building a new world of patient care with its groundbreaking medical visualization software. The company's FDA-cleared True 3D Viewer uses existing medical image datasets to create virtual reality environments of patient-specific anatomy, allowing physicians to view and dissect images just as they would real, physical objects. The technology aims to make reading medical images more intuitive, help physicians reach diagnosis, and assist in surgical planning. Leading institutions, including the University of California, San Francisco, the Cleveland Clinic, the Lahey Clinic, and more are using True 3D in clinical and research applications. EchoPixel is a privately held, venture backed company located in Mountain View, CA.
Rutter M.K.,University of Manchester |
Nesto R.W.,Lahey Clinic
European Heart Journal | Year: 2011
Epidemiological studies have clearly shown a direct relationship between the levels of blood pressure, glycaemia and LDL-cholesterol, and the complications of diabetes. Although 'lower should be better, the results of recent clinical trials examining the benefits of normalizing risk factor levels have been counter-intuitive and, at times, disturbing, and have called into question this notion. This review focuses on patients with type 2 diabetes who make up 90 of patients with diabetes. It aims to provide a clear summary and interpretation of recent trials to help clinicians to set targets for cardiovascular risk factors in individual patients. It highlights areas of agreement and disagreement between current guidelines. Recent data indicate that some patient subgroups might respond differently to aggressive risk factor management. Our challenge is how to identify these patients and deliver truly personalized diabetes care that maximizes benefit, and minimizes harm. Guidelines and position statements stress the value of setting personalized targets. We explore what this means, and how this might be achieved in practice by outlining some solutions to issues that currently limit the delivery of personalized care. We call for further research assessing the overall clinical impact of cardiovascular risk factor intervention by finding appropriate ways of combining data on mortality, complications, side-effects, quality of life, and cost-effectiveness. © 2011 The Author.
Mantha S.,Lahey Clinic |
Ansell J.,New Hill
Thrombosis and Haemostasis | Year: 2012
New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation. Two agents are direct factor Xa inhibitors (rivaroxaban and apixaban), and the third is a direct thrombin inhibitor (dabigatran). They have been separately compared to warfarin in large randomised trials. Our objective was to indirectly compare the three agents to each other for major efficacy and safety outcomes. Studies were assessed for comparability and the odds ratios of selected outcomes for each anticoagulant versus one another were estimated indirectly. The three cohorts differed significantly in terms of CHADS2 score and the number of individuals with a past history of stroke, transient ischemic attack or systemic embolism. The estimated odds ratio of stroke or systemic embolism was 1.35 for rivaroxaban vs dabigatran 150 mg (p=0.04), 0.97 for rivaroxaban versus dabigatran 110 mg (p=0.81), 1.22 for apixaban versus dabigatran 150 mg (p=0.18), 0.88 for apixaban versus dabigatran 110 mg (p=0.34) and 0.90 for apixaban versus rivaroxaban (p=0.43). The estimated odds ratio of major bleeding was 1.10 for rivaroxaban versus dabigatran 150 mg (p=0.36), 1.28 for rivaroxaban versus dabigatran 110 mg (p=0.02), 0.74 for apixaban versus dabigatran 150 mg (p=0.004), 0.87 for apixaban versus dabigatran 110 mg (p=0.17) and 0.68 for apixaban versus rivaroxaban (p<0.001). In conclusion, the available data indicate no significant difference in efficacy between dabigatran 150 mg and apixaban for the prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation. It appears however that apixaban is associated with less major bleeding than dabigatran 150 mg or rivaroxaban and that rivaroxaban is less effective than dabigatran 150 mg in preventing stroke or systemic embolism. Such an indirect comparison should be used only to generate hypotheses which need to be tested in a dedicated randomised trial comparing the three drugs directly. © Schattauer 2012.
Scholz F.J.,Lahey Clinic
Radiographics | Year: 2011
Celiac disease is now recognized as a common disease, occurring in about one in every 200 Americans. However, less than 10% of cases are currently diagnosed, with a diagnostic delay of more than 10 years from onset of symptoms. In the past, barium examination of the small bowel demonstrated a pattern of abnormal findings caused by the pathophysiologic changes induced by malabsorption, thus leading to diagnosis of celiac disease and other diseases of malabsorption. Although not specific, that pattern prompted further patient evaluation. The number of barium examinations performed and the skill necessary to interpret their results are both in decline. Abdominal pain in celiac disease is a common early complaint that often leads to computed tomography (CT). Improved CT resolution now permits better depiction of the small bowel, colon, and mesenteric lymph nodes, all of which are affected by celiac disease. Detection of celiac disease with CT will allow treatment to be initiated to prevent the significant morbidity and increased mortality associated with a delay in diagnosis. The abnormal CT findings seen over the past decade during review of more than 200 cases of celiac disease demonstrate that CT depicts more features of celiac disease than did barium examination. Pattern recognition for the diagnosis of small bowel diseases that create structural changes in the bowel wall is well accepted. Because it demonstrates features of celiac disease not detected with barium examination, CT may be more sensitive than barium examination for diagnosis of this disease. © RSNA, 2011.
Stoffel J.T.,Lahey Clinic
Urologic Clinics of North America | Year: 2010
Urinary symptoms related to multiple sclerosis (MS) present a complex challenge for the treating physician. However, several treatment options are available for the symptomatic patient once the physician understands basic MS disease epidemiology and pathophysiology. Depending of disease status and symptoms, MS urinary symptoms may respond to directed behavioral, pharmacologic, intravesical, neuromodulation, or surgical therapies. © 2010 Elsevier Inc.
Jacoby G.A.,Lahey Clinic |
Hooper D.C.,Massachusetts General Hospital
Antimicrobial Agents and Chemotherapy | Year: 2013
qnr genes were discovered on plasmids by their ability to reduce quinolone susceptibility, but homologs can be found in the genomes of at least 92 Gram-negative, Gram-positive, and strictly anaerobic bacterial species. The related pentapeptide repeat protein-encoding mfpA gene is present in the genome of at least 19 species of Mycobacterium and 10 other Actinobacteria species. The native function of these genes is not yet known. Copyright © 2013, American Society for Microbiology. All Rights Reserved.
Gaasch W.H.,Lahey Clinic |
Zile M.R.,Medical University of South Carolina
Journal of the American College of Cardiology | Year: 2011
The changes in left ventricular (LV) structure and geometry that evolve after myocardial injury or overload usually involve chamber dilation and/or hypertrophy. Such architectural remodeling can be classified as eccentric or concentric. Consideration of LV volume, mass, and relative wall thickness (or mass/volume) allows classification of LV remodeling that includes virtually all LV remodeling changes that are seen in health and disease. These various architectural changes generally include the development of LV hypertrophy in a pattern that is closely related to the type of injury or overload, and they are accompanied by differences in cardiac function and hemodynamics. Some patterns of remodeling are associated with adverse outcomes whereas others appear to be adaptive and physiologic without adverse consequences. Considering all patients with LV hypertrophy as a homogenous group is inconsistent with our understanding of the various remodeling patterns that are discussed in this review. © 2011 American College of Cardiology Foundation.
Schnelldorfer T.,Lahey Clinic
Journal of Gastrointestinal Surgery | Year: 2013
Background: Gallbladder wall calcifications, otherwise known as porcelain gallbladder, have received considerable attention due to its perceived association with gallbladder carcinoma. While the perception of a strong correlation persists, more recent reports raise conceivable doubts. Study Design: A systematic literature search was conducted of human studies describing gallbladder wall calcification and its association with gallbladder malignancy. Results: The 111 articles which met inclusion criteria identified 340 patients with gallbladder wall calcification. Of the 340 patients, 72 (21 %) were diagnosed with malignancy of the gallbladder. When examining a subgroup of 13 studies (n = 124) without obvious selection bias, the rate of gallbladder malignancy was only 6 % (0-33 %) compared to 1 % (0-4 %) in a matched cohort of patients without gallbladder wall calcification (p = 0.036, relative risk 8.0 (95%CI 1.0-63.0)). Multivariate analysis identified the presence of symptoms typical for gallbladder cancer (odds ratio 83.6, 95%CI 2.3-2979.1, p = 0.015) and the presence of a gallbladder mass (odds ratio 3226.6, 95%CI 17.2-603884.8, p = 0.003) as the only independent prognostic factors for harboring gallbladder malignancy. Conclusions: The risk of harboring gallbladder cancer in patients with gallbladder wall calcifications is lower than recently anticipated. The risk factors identified have only limited clinical value, since they are stigmatic for advanced gallbladder cancer. In the absence of better risk stratification and in the presence of a relative low rate of associated malignancy, prophylactic cholecystectomy appears appropriate for otherwise healthy patients; whereas a non-operative approach should be considered in patients with significant co-morbidity. © 2013 The Society for Surgery of the Alimentary Tract.
News Article | October 28, 2016
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting bladder cancer through endoscopes VANCOUVER, BC and BOSTON, MA--(Marketwired - October 27, 2016) - Imagin Medical ( : IME) ( : IMEXF) ( : DPD2) (the "Company") announced today that Dr. Liam J. Hurley, a member of the Northeast Urologic Surgery, PC, has joined Imagin's Scientific Board of Advisors. Dr. Hurley obtained his Bachelor of Arts degree from Harvard University and his M.D. from Boston University School of Medicine. After spending three years in the U.S. Navy, he completed a General Surgery Residency at St. Elizabeth's Medical Center of Boston and his Urology Residency at the Lahey Clinic in Burlington, MA. He is trained as an adult and pediatric urologist with expertise in genitourinary oncology. Dr. Hurley is a private practice community urologist who has clinical affiliations with Tufts New England Medical Center and Lahey Clinic. Other accomplishments include launching The Boston Urologic Society, serving on the Executive Committee for the Massachusetts Association of Practicing Urologists, and presiding as the Eastern Massachusetts representative to the New England Section of the AUA. Dr. Hurley is Board certified in Urology and is a Fellow of the American College of Surgeons. In 2006, he was chosen as one of Boston's "TOP DOCTORS" by Boston Magazine. "Dr. Hurley's knowledge and expertise in the urology field will be a great asset to our Advisory Board," said Jim Hutchens, Imagin President and CEO. "We look forward to his joining our team as we continue to add relevant expertise to help Imagin succeed." About Imagin Medical Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com. ON BEHALF OF THE BOARD: Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.